REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Clinical trials for REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising new combo targets rare infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with chemotherapy for infants and young children with a hard-to-treat leukemia that has returned or not responded to treatment. The drug targets a specific genetic change (KMT2A rearrangement) that drives the cancer. The goal …
Matched conditions: REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
New drug combo offers hope for kids with relapsed leukemia
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs, selinexor and venetoclax, when added to standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study involves 37 participants and ai…
Matched conditions: REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 12:04 UTC